FDA: ‘Elevidys Gene Therapy Will Continue to Be Used in Ambulatory DMD Patients’

July 29, 2025 DMDWarrioR

In a statement Monday, it said the FDA's swift action eliminated a problem with Sarepta, allowing Elevidys to return to the market without another safety study as had been feared.

Read More Press Releases

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

January 5, 2025 DMDWarrioR

The results of new gene therapy studies for Duchenne muscular dystrophy disease will be watched by curious eyes in 2025.

Read More Research

Next Generation Exon Skipping Therapies Developed for the Treatment of DMD

January 16, 2025 DMDWarrioR

Next generation exon skipping therapies for Duchenne Muscular Dystrophy (DMD) represent a promising area of research aimed at addressing the underlying genetic mutations that cause the disease.

Read More Research

We Call on Health Ministries and Pharmaceutical Manufacturers to Take Action on DMD

February 16, 2025 DMDWarrioR

We call on all health ministries around the world and manufacturers of DMD treatments approved by the FDA and EMA to take action.

Read More Editorials

DMD WarrioR’s Turkish Representative Shares His Views on Elevidys Gene Therapy

March 28, 2025 DMDWarrioR

We spoke to DMDWarrioR's Turkiye Representative about his perspective and concerns regarding Elevidys gene therapy. We also received surprising information about DMD studies in Turkiye.

Read More Editorials

Is Elevidys Cost Worthy? Clinical Trials Review of Elevidys Gene Therapy

March 2, 2025 DMDWarrioR

Is Elevidys Effective and Cost Worthy Compared to Clinical Trials?

Read More Editorials

Why Isn’t Roche Applying Marketing Authorization in Every Country for Elevidys Gene Therapy?

March 13, 2025 DMDWarrioR

If you are wondering when Elevidys gene therapy will come to your country, this article may help you get an idea.

Read More Editorials

What is Duchenne Muscular Dystrophy?

September 14, 2024 DMDWarrioR

Duchenne Muscular Dystrophy (DMD) is a genetic disorder that affects thousands of families worldwide. It primarily impacts boys, causing muscle degeneration and weakness over...

Read More DMD

Genetic Causes of Duchenne Muscular Dystrophy

October 4, 2024 DMDWarrioR

Duchenne muscular dystrophy (DMD) is rooted in the intricate world of genetics, specifically emanating from changes in a single gene known as the Dystrophin...

Read More DMD

Does My Child Have Duchenne Muscular Dystrophy (DMD)?

October 4, 2024 DMDWarrioR

When parents ponder the question, “Does My Child Have Duchenne Muscular Dystrophy (DMD)?” they often find themselves grappling with a whirlwind of emotions as...

Read More DMD

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

January 5, 2025 DMDWarrioR

The results of new gene therapy studies for Duchenne muscular dystrophy disease will be watched by curious eyes in 2025.

Read More Research

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

January 5, 2025 DMDWarrioR

The results of new gene therapy studies for Duchenne muscular dystrophy disease will be watched by curious eyes in 2025.

Read More Research
Is Elevidys Effective and Cost Worthy Compared to Clinical Trials? Roche Marketing Authorization Strategy in Every Country for Elevidys Gene Therapy. We spoke to DMDWarrioR's Turkiye Representative about his perspective and concerns regarding Elevidys gene therapy. We also received surprising information about DMD studies in Turkiye. FDA: ‘Elevidys Gene Therapy Will Continue to Be Used in Ambulatory DMD Patients’

About our Mission

Many people in the world do not know what Duchenne muscular dystrophy is. Because only one in every 5,000 boys gets this disease. However, families and their surroundings whose children struggle with this disease have to live with the stress of this disease every day. We call them DMD Warriors.

DMDWarrior.com was established to raise awareness of this disease worldwide, facilitate access to treatments, and ensure that treatment costs are affordable.

dmd warrior dmdwarrior

What is our purpose?

One in every 5,000 children in the world is born with DMD, and many families only realize their child has the disease when they are 3-4 years old. FDA-approved treatments for DMD are too expensive for families to afford. Our goal is to reduce treatment costs and have the costs covered by the government.

Home

Ease of Access to Treatments

In many countries, DMD treatments are not available, and families incur huge costs for travel abroad.

Home

Reducing Treatment Costs

Treatments for DMD are very expensive, and it is nearly impossible for families to cover these costs themselves.

Home

Raising Awareness on Social Media

We do not want any child to die. If you also want to find a solution to this situation, follow us on social media.

News & Articles

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

ITF Therapeutics affiliate of Italfarmaco, today announced publication of positive long-term safety and efficacy data for Duvyzat (Givinostat) as a treatment for Duchenne muscular...

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Keros Therapeutics today announced the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy...

ITF Therapeutics Launching A Study to Evaluate the Real-World Experience of Duvyzat (Givinostat) in Patients With Duchenne Muscular Dystrophy

The purpose of this prospective observational study (NCT07127978) is to assess the safety, tolerability, and functional results of DMD patients who are starting oral...

Agamree to be sold in United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain starting in 2026

Santhera Pharmaceuticals announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, the...

Santhera Secures Agreement with GEN for the Distribution of AGAMREE (Vamorolone) in Turkiye

Santhera Pharmaceuticals announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and...